Please use this identifier to cite or link to this item:
https://hdl.handle.net/11499/47353
Title: | Evaluation of hepatitis serology and frequency of viral reactivation in patients with inflammatory arthritis receiving biologic agents: a multicenter observational study | Authors: | Capkin E. Yazıcı A. Karkucak M. Durmaz Y. Toprak M. Ataman Ş. Şahin N. Cuzdan, Nihan Kasapoglu Aksoy, Meliha Onder, Mustafa Erkut Serdaroglu Beyazal, Munevver Mesci, Nilgun Baykul, Merve Alkan Melikoglu, Meltem Alkan, Hakan Dulgeroglu, Deniz Cengiz, Ahmet Kivanc Nas, Kemal Balevi Batur Elif Caliskan Uckun, Asli Deveci, Hulya Erol, Kemal Albayrak Gezer, Ilknur Akgol, Gurkan Duruoz, Mehmet Tuncay Kucukakkas, Okan Sarikaya, Selda Rezvani, Aylin Atan, Tugba Gogus, Feride Caglayan, Gokhan Keskin, Yasar Bulut Keskin, Ayse Selcen Oz, Nuran Yilmaz, Gurdal |
Keywords: | Biologic agents Hepatitis Inflammatory arthritis Viral reactivation |
Publisher: | Springer Science and Business Media Deutschland GmbH | Abstract: | To evaluate of hepatitis serology and reactivation frequency in patients with rheumatic disease receiving biologic agents. Our study included patients with inflammatory rheumatic diseases from 23 centers, who were followed up with biological therapy. Demographic and clinical characteristics of the patients, duration of drug use and hepatitis serology and the state of viral reactivation were analyzed. A total of 4060 patients, 2095 being males, were included in our study. Of the patients, 2463 had Ankylosing Spondylitis (AS), 1154 had Rheumatoid Arthritis (RA), 325 had Psoriatic Arthritis (PsA), and 118 had other inflammatory rheumatic diseases. When the viral serology of the patients was evaluated, 79 patients (2%) who were identified as HBs Ag positive, 486 (12%) patients who were HBs Ag negative and anti-HBc IgG positive and 20 patients (0.5%) who were anti-HCV positive. When evaluated on a disease-by-disease basis, the rate of HBsAg was found to be 2.5% in RA, 2% in AS and 0.9% in PsA. Viral reactivation was detected in 13 patients while receiving biologic agents. HBs Ag was positive in nine patients with reactivation and negative in four patients. Anti-HBc IgG, however, was positive. Six of these patients had AS, four had RA, and three had PsA. The development of hepatitis reactivation in 11.4% of HBs Ag positive patients and 0.82% of anti-HBc IgG positive patients due to the use of biologic agents is an important problem for this group of patients. Antiviral prophylaxis is recommended to be started especially in patients who are HBs Ag positive and who are using biologic agents due to viral reactivation. Therefore, it is important to carry out hepatitis screenings before biologic agent treatment and to carefully evaluate the vaccination and prophylaxis requirements. © 2022, The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature. | Description: | Article; Early Access | URI: | https://doi.org/10.1007/s00296-022-05169-2 https://hdl.handle.net/11499/47353 |
ISSN: | 0172-8172 |
Appears in Collections: | PubMed İndeksli Yayınlar Koleksiyonu / PubMed Indexed Publications Collection Scopus İndeksli Yayınlar Koleksiyonu / Scopus Indexed Publications Collection Tıp Fakültesi Koleksiyonu WoS İndeksli Yayınlar Koleksiyonu / WoS Indexed Publications Collection |
Show full item record
CORE Recommender
SCOPUSTM
Citations
1
checked on Oct 13, 2024
WEB OF SCIENCETM
Citations
2
checked on Oct 31, 2024
Page view(s)
60
checked on Aug 24, 2024
Google ScholarTM
Check
Altmetric
Items in GCRIS Repository are protected by copyright, with all rights reserved, unless otherwise indicated.